Shukra Pharmaceuticals Complete Financial Statements
In FY2026, Shukra Pharmaceuticals (SHUKRAPHAR) reported revenue ₹7 Cr, net profit ₹-2 Cr and EPS ₹-0.04, with a net profit margin of -28.6% and ROE of -2.2%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Shukra Pharmaceuticals share price today.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SHUKRAPHAR Revenue, Net Profit & EBITDA — Year-on-Year Growth
SHUKRAPHAR YoY (Mar 2025 vs Mar 2026) — revenue -53.3%, net profit -140.0%, EBITDA -77.8%. Examine SHUKRAPHAR Q4 results for recent quarterly revenue, profit and EPS trends.
SHUKRAPHAR Income Statement — Revenue, EBITDA & Net Profit
Shukra Pharmaceuticals revenue ₹7 Cr, EBITDA ₹2 Cr, net profit ₹-2 Cr, EPS ₹-0.04 (2026) — net profit margin -28.6%. Analyse SHUKRAPHAR FII DII holdings to track promoter, FII and institutional holdings.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Dec 2024 |
|---|---|---|---|---|---|---|
| Revenue | 7 | 8 | 15 | 7 | 40 | 12 |
| Expenses | 6 | 6 | 6 | 4 | 12 | 7 |
| EBITDA | 2 | 1 | 9 | 2 | 28 | 5 |
| Operating Profit Margin % | 11.00% | -7.00% | 55.00% | 24.00% | 69.00% | 37.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 8 | 1 | 27 | 4 |
| Tax | 2 | -2 | 2 | 0 | 7 | 1 |
| Net Profit | -2 | 2 | 5 | 1 | 20 | 3 |
| Earnings Per Share (₹) | -0.04 | 0.05 | 0.12 | 0.02 | 0.47 | 0.72 |
SHUKRAPHAR Balance Sheet — Assets, Liabilities & Shareholders' Equity
SHUKRAPHAR total assets ₹117 Cr, total equity ₹90 Cr, total liabilities ₹ Cr (2026) — ROE -2.2%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 117 | 87 | 78 | 75 | 35 | 36 | 34 | 28 | 24 | 19 | 17 | 18 |
| Current Assets | 84 | 65 | 56 | 53 | 16 | 16 | 15 | 11 | 8 | 7 | 6 | 7 |
| Fixed Assets | 34 | 19 | 20 | 20 | 18 | 18 | 17 | 16 | 14 | 10 | 10 | 10 |
| Capital Work in Progress | 12 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Investments | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 65 | 56 | 53 | 16 | 16 | 15 | 11 | 8 | 7 | 6 | 7 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 5 | 7 | 6 | 7 | 6 | 13 | 11 | 9 | 6 | 3 | 3 | 4 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 90 | 63 | 58 | 25 | 16 | 16 | 15 | 15 | 15 | 15 | 14 | 14 |
| Share Capital | 44 | 44 | 11 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves & Surplus | 46 | 19 | 47 | 21 | 15 | 14 | 14 | 14 | 13 | 13 | 13 | 12 |
SHUKRAPHAR Cash Flow Statement — Operating, Investing & Financing
Shukra Pharmaceuticals operating cash flow ₹8 Cr, investing ₹-1 Cr, financing ₹-5 Cr, net cash flow ₹2 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 8 | -5 | 3 | 8 | 1 | 1 | 0 | 1 | 0 | 3 | -2 |
| Investing Activities | -1 | -1 | -4 | -2 | -2 | -3 | -3 | -5 | -1 | 0 | 1 |
| Financing Activities | -5 | 12 | 5 | -7 | 2 | 2 | 2 | 4 | 0 | -1 | 1 |
| Net Cash Flow | 2 | 6 | 4 | 0 | 0 | 0 | 0 | -1 | -1 | 1 | 0 |